Home › Mieloma multiplo › Oregon › Portland
Studi clinici su Mieloma multiplo a Portland, OR
13 studi su Mieloma multiplo cercano partecipanti presso sedi a Portland e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
In reclutamentoFase 3
- Research Site, Portland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 3
- Oregon Health And Science University, Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
In reclutamentoStudio osservazionale
- OHSU Knight Cancer Institute, Portland
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
In reclutamentoFase 2
- Providence Health & Services, Portland
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 2
- Oregon Health and Science University, Portland
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
In reclutamentoFase 1/2
- Oregon Health and Science University /ID# 272282, Portland
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
In reclutamentoFase 1
- Providence Portland Medical Center, Portland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
In reclutamentoFase 3
- Research Site, Portland
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
In reclutamentoFase 2
- Oregon Health & Science University, Portland
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · a 12 mi di distanza
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1/2
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
In reclutamentoStudio osservazionale
- Local Institution - 0016, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Oregon Health Sciences University, Portland
Studi su Mieloma multiplo in altre città
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
Altri studi a Portland
- Cancro del polmone non a piccole cellule46 studi
- Cancro (tutti i tipi)34 studi
- Cancro alla prostata33 studi
- Cancro al seno33 studi
- Cancro metastatico29 studi
- Cancro colorettale28 studi
- Cancro ovarico27 studi
- Cancro ai polmoni26 studi
- Leucemia mieloide acuta25 studi
- Cancro dell'endometrio24 studi
- Carcinoma a cellule squamose della testa e del collo19 studi
- Cancro pancreatico19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.